[STRATEGIC] Biopharma
· Oncology ·
Leukemia / Hematology — Announced March 25, 2026 — Expected Close Q2
2026
Merck Strikes Again: $6.7B Acquisition of
Terns Pharmaceuticals Deepens Its Hematology Pipeline Ahead of Keytruda's
Patent Cliff
Merck's third multi-billion dollar acquisition in twelve months:
the Rahway pharma giant pays $53/share for a clinical-stage biotech whose
TERN-701 — a next-generation oral leukemia drug — could command multi-billion
dollar peak sales and provide a meaningful offset to the ~$20B Keytruda revenue
loss expected as patents expire from 2028.
DEAL SNAPSHOT
|
EQUITY VALUE $6.7 Billion |
EXPECTED CLOSE Q2 2026 |
|
NET OF CASH $5.7 Billion |
PRICE PER SHARE $53.00 (all-cash) |
|
ANNOUNCED March 25, 2026 |
PREMIUM (60-DAY VWAP) 31% / 42% to 90-day VWAP |
THE PARTIES
|
ACQUIRER Merck & Co., Inc.
(NYSE: MRK) Rahway,
NJ-based global pharmaceutical company. Chairman & CEO Robert M. Davis.
FY2025 revenues ~$64B, driven primarily by Keytruda (pembrolizumab) — the
world's best-selling cancer drug at ~$29B in 2025 sales. Keytruda faces a
critical patent cliff beginning in 2028. Merck has been on a multi-billion
dollar acquisition spree — Prometheus Biosciences ($10.8B, 2023), Harpoon
Therapeutics ($680M, 2023), EyeBio ($1.3B, 2024) — to refill its pipeline
ahead of this cliff. This is Merck's third $1B+ deal in twelve months. |
TARGET Terns Pharmaceuticals, Inc.
(Nasdaq: TERN) Foster City,
CA-based clinical-stage oncology company. CEO Mark Vignola.
FY2025 revenues minimal (pre-commercial). Lead asset: TERN-701, an investigational oral allosteric
BCR::ABL1 tyrosine kinase inhibitor (TKI) for patients with Philadelphia
chromosome-positive chronic phase chronic myeloid leukemia (CML). Being
evaluated in the Phase I/II Cardinal trial. Terns' stock surged ~6x in the
six months prior to announcement on strong clinical data and takeover
speculation. |
DEAL OVERVIEW
Merck agreed to
acquire all outstanding shares of Terns for $53.00 per share in cash —
representing an approximate 31% premium to Terns' 60-day VWAP and a 42% premium
to its 90-day VWAP as of March 24, 2026. The $6 premium to the prior day's
close (6%) reflects that Terns' stock had already surged dramatically on
takeover speculation, making the absolute premium to VWAP the more meaningful
benchmark.
The transaction
is structured as a cash tender offer followed by a second-step merger. Under
HSR antitrust review, both boards have unanimously approved the deal. Merck
expects to account for the transaction as an asset acquisition (given Terns'
pre-commercial stage), recording a one-time charge of approximately $5.8
billion in Q2 and full-year 2026 GAAP and non-GAAP results. Close is expected
in Q2 2026.
"TERN-701 has shown compelling early clinical data that
reinforces its potential to address a significant unmet need. This acquisition
is consistent with our strategy of building a robust oncology pipeline to drive
long-term growth."
— Robert M.
Davis, Chairman & CEO, Merck
THE ASSET: TERN-701 AND THE CML MARKET
CML (Chronic
Myeloid Leukemia) is a blood cancer caused by the BCR::ABL1 fusion oncogene.
The market has been transformed by oral TKI drugs (imatinib/Gleevec,
dasatinib/Sprycel), but a meaningful subset of patients — those who relapse
after, are resistant to, or intolerant of existing TKIs — have limited
treatment options. TERN-701 is an allosteric inhibitor that targets a different
binding site on BCR::ABL1, allowing it to potentially overcome resistance
mutations that defeat existing drugs.
Phase I/II
Cardinal trial results have been described by oncologists as "highly
promising," with response rates that compare favorably to approved TKIs in
this difficult-to-treat population. Merck's existing hematology infrastructure
— built through prior acquisitions and internal development — provides a ready
platform into which TERN-701 can be integrated for Phase III development.
ADVISORS
Sell-side
Financial (Terns): Centerview
Partners LLC + Jefferies LLC
Sell-side
Legal (Terns): Freshfields LLP
No financial
advisors were publicly disclosed for Merck. Given Merck's well-resourced
internal corporate development team, the buy-side was likely managed in-house
with legal counsel.